• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Forner-Cordero I, Herrero-Manley L, Garcia-Marcos R, Munoz-Langa J. Various Clinical Scenarios in Secondary Malignant Lymphedema. Lymphology 2022;55:144-154. [PMID: 37553003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/10/2023]
2
Forner-Cordero I, Perez-Pomares MV, Forner A, Ponce-Garrido AB, Munoz-Langa J. Prevalence of clinical manifestations and orthopedic alterations in patients with lipedema: A prospective cohort study. Lymphology 2021;54:170-181. [PMID: 35073621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
3
Salgado M, Sepulveda Sanchez J, del barco S, Pineda E, Fuster J, Navarro Martin M, Herrero Ibañez A, Alonso M, Perez J, Mesia C, Munoz-Langa J, de las Penas Bataller R, Peralta S, Olier C, Pérez-Segura P, Estival A, Carrato C, Saez C, Gil M, Balana C. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
4
Pérez-Valderrama B, Arranz Arija J, Chirivella González I, Anido Herranz U, Jurado García J, Suarez Rodriguez C, García Carbonero I, de Velasco G, García Domínguez R, García Marrero R, Gonzalez Del Alba Baamonde M, Molins Palau C, Lazaro M, Munoz-Langa J, Martinez Ortega E, Hernández Jorge A, Campayo Guillaumes M, Sereno Moyano M, Luque Caro R, Rodríguez Sánchez Á. SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA